Compare Consolidated Edison, Inc. (ED) vs TransMedics Group Inc (TMDX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Consolidated Edison, Inc. vs TransMedics Group Inc — how do they compare? Consolidated Edison, Inc. trades at $106.11 (market cap $39.20B), while TransMedics Group Inc trades at $79.01 (market cap $2.74B). The key difference: Consolidated Edison, Inc. is far larger — about 14.3× TransMedics Group Inc's market cap, and Consolidated Edison, Inc. pays a 3.31% dividend while TransMedics Group Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Consolidated Edison, Inc. for 75 Days and TransMedics Group Inc for 24 Days on average.
| ED | TMDX | |
|---|---|---|
Market Cap | $39.20B | $2.74B |
Volume | 2,142,900 | 949,331 |
Sector | Utilities | Health |
52-Week High | $115.46 | $150.42 |
52-Week Low | $95.37 | $61.99 |
Typical Hold Time | 75 Days | 24 Days |
Enterprise Value | $66.05B | $3.13B |
Dividend Yield | 3.31% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Consolidated Edison (ED) trades at $104.65, down 0.45% on the day, with a mixed technical outlook showing a bullish overall signal but bearish moving averages. The company reported revenue of $16.92B and net income of $2.02B for 2025, with a net margin of 11.95%. Recent earnings have been mixed, with a beat in Q2 2026 but a miss in Q1 2026. The stock is supported by a strong dividend history, with a recent $0.89 dividend declared for H2 2026, and positive news highlighting its economic impact in New York and involvement in electric bus infrastructure.
The outlook for ED is cautiously optimistic, with a consensus price target of $106.33 suggesting modest upside. Strengths include stable cash flow, a solid dividend, and strategic investments in infrastructure. Key risks involve fluctuating earnings, high debt levels, and regulatory pressures. Analyst sentiment is predominantly neutral, with 62.96% hold ratings, indicating a wait-and-see approach amid evolving utility sector dynamics.
TMDX trades at $81.07, up 0.98% today, but faces a bearish technical signal with recent price weakness. Fundamentally, the company reported strong 2025 results with $605.49M revenue and $190.29M net income, though 2026 projections show margin compression. Recent news highlights insider buying and ongoing legal investigations into fiduciary duties, creating mixed sentiment.
The stock offers potential upside to the $99.75 consensus target, supported by a 69% buy rating from analysts, but risks include earnings misses, margin pressure from heavy investment, and legal overhangs. Execution on growth amid rising costs remains critical for sustaining its premium valuation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →About TransMedics Group Inc
TransMedics is a pioneering medical technology company that is disrupting the organ transplant market with its Organ Care System (OCS™). By replacing traditional cold storage with portable warm perfusion, the OCS maintains donor organs in a near-physiologic state, allowing for continuous assessment and optimization. Through its National OCS Program (NOP™), TransMedics provides an end-to-end clinical and logistics solution, including a dedicated aviation fleet, to maximize the utilization of donor organs and improve patient outcomes.
Read more on TMDX →
